Table 2.

Treatment-Related Adverse Events in ≥10% of Patients

	Any grade, N = 18	Grade 3 or 4, N = 18
Event	No. of patients (%)
Any treatment-related adverse event	18 (100%)	14 (78%)
Nausea	16 (89%)
Diarrhea	15 (84%)
Hypophosphatemia	13 (72%)	10 (56%)
Fatigue	12 (67%)
Abdominal pain	10 (56%)	1 (6%)
Weight loss	9 (50%)	1 (6%)
Anorexia	7 (39%)	1 (6%)
Mucositis	7 (39%)
Dry mouth	7 (39%)
Dysgeusia	6 (33%)
Vomiting	6 (33%)
Skin disorders	6 (33%)
Aspartate aminotransferase increased	5 (28%)	1 (6%)
Constipation	4 (22%)
High cholesterol	3 (17%)
Hypertriglyceridemia	3 (17%)
Infection	3 (17%)
Pruritis	3 (17%)	1 (6%)
Alanine aminotransferase increased	2 (11%)
Anemia	2 (11%)
Headache	2 (11%)
Seizure	2 (11%)
Dyspareunia	2 (11%)